About Us

transforming how the world preserves & transports biology - without cryopreservation.

Atelerix provides patented alginate hydrogel technology to stabilise cells, tissues, blood products, viruses & vectors at room temperature. From discovery research to clinical logistics, Atelerix helps scientists preserve viability, cut costs, & simplify global transport.

Welcome to the marvellous future of bioscience, where storage is a doddle & cells remain impeccably fresh!

What even is an atelerix?

Enter the hedgehog, or more specifically, its scholarly alias, Atelerix. our muse? the African four-toed pygmy hedgehog, a tiny creature with the magical ability to hit the pause button & hibernate when the mercury dips below the cosy mark of 20°C.

And just like that, with a dash of geeky delight & a nod to our spiky little friends, Atelerix was conjured into existence. we may not be able to curl up in a ball & snooze the winter away, but by golly, we can sure keep your cells, tissues, & viruses in a state of happy hibernation until they're ready to wake up & get to work!

Born in the lab. Built for the world

Atelerix was founded by a team of scientists who saw the limitations of cryopreservation - and knew there had to be a better way.

Spun out from world-class research in Newcastle, our company has grown into a platform for scalable, ambient preservation.

Today, we’re helping researchers, biotech firms and diagnostics teams store and ship cells and tissues, without the cold chain.

2012

Foundational Discovery

Breakthrough discovery that alginates can preserve viable cells at room temperature, revealing a transformative approach to overcoming cold-chain limitations in cell logistics and therapy.

2012

Intellectual Property Initiation

First patent filed, securing the core innovation that would underpin Atelerix’s future biopreservation platform.

2013-2016

Academic Research & Proof-of-Concept

Extensive R&D at Newcastle University, led by Dr. Steve Swioklo and Prof. Che Connon, validating the science and demonstrating broad applicability across cell and tissue types.

2017

Company Formation

Atelerix Ltd incorporated, marking the transition from academic innovation to commercial enterprise.

2017-2019

Technology Validation & Market Introduction

Development and soft-launch of three pioneering products - BeadReady, WellReady, and TissueReady - enabling the cold-chain-free preservation of cells, in-plate models, and tissues.

Early adopters validated the platform’s performance, usability, and market relevance.

2018

Strengthening IP Portfolio

Second patent filed, expanding the company’s intellectual property base and reinforcing competitive advantage.

2020

Regulatory Milestone

Achieved first regulatory approval for product use in a clinical trial, supporting an ocular cell-based therapy - a key milestone affirming the platform’s safety and translational potential.

2020

IP Expansion & Pipeline Development

Third patent filed and focused technology development for blood products and viral preservation, extending the platform into emerging therapeutic and diagnostic markets.

2022-2024

Product Portfolio Expansion & Scaling Adoption

Soft-launch of four new products - LeukoStor, BloodReady, CytoStor, and TissueReady-PLUS - addressing unmet needs in leukapheresis, whole blood, viral, and tissue sample preservation.

These launches drove broad adoption across biotech, diagnostics, and clinical research sectors, validating repeatable demand and clear market fit.

2024

Brand Evolution & Commercial Momentum

Completed a strategic rebrand to align with market maturity.

Commenced full commercial deployment and international scaling, establishing Atelerix as a recognised leader in ambient biopreservation.

Initiated global partnerships with biopharma, clinical, and research organisations, driving commercial uptake and revenue growth.

Fourth patent filed, securing innovations underpinning next-generation formulations.